Compare UNH & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UNH | MRK |
|---|---|---|
| Founded | 1977 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 386.3B | 317.8B |
| IPO Year | 2010 | 1994 |
| Metric | UNH | MRK |
|---|---|---|
| Price | $427.90 | $126.26 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 26 | 17 |
| Target Price | ★ $384.50 | $125.59 |
| AVG Volume (30 Days) | 5.9M | ★ 8.2M |
| Earning Date | 04-21-2026 | 04-30-2026 |
| Dividend Yield | 2.38% | ★ 3.06% |
| EPS Growth | N/A | ★ 8.01 |
| EPS | ★ 6.90 | N/A |
| Revenue | ★ $447,567,000,000.00 | $65,011,000,000.00 |
| Revenue This Year | N/A | $3.61 |
| Revenue Next Year | $3.64 | $5.41 |
| P/E Ratio | $62.01 | ★ N/A |
| Revenue Growth | ★ 11.81 | 1.31 |
| 52 Week Low | $234.60 | $76.66 |
| 52 Week High | $430.20 | $130.29 |
| Indicator | UNH | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 62.50 | 58.18 |
| Support Level | $314.99 | $112.68 |
| Resistance Level | N/A | $130.29 |
| Average True Range (ATR) | 9.71 | 3.23 |
| MACD | -0.00 | 0.51 |
| Stochastic Oscillator | 88.28 | 80.53 |
UnitedHealth Group is one of the largest private health insurers and provides medical benefits to about 51 million members globally, including 1 million outside the US as of December 2025. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in medical insurance. Along with its insurance assets, UnitedHealth's Optum franchises help create a healthcare services colossus that spans everything from pharmaceutical benefits to providing outpatient care and analytics to affiliates and third parties.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).